Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
Pearl Toh, 5 days ago
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.
Elvira Manzano, 20 Jun 2018
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.

Relugolix represents oral alternative to injectable androgen deprivation therapies

25 May 2020

In patients with localized prostate cancer undergoing external beam radiotherapy (EBRT), use of the orally administered androgen deprivation therapy (ADT) relugolix results in rapid and sustained suppression of testosterone to castrate levels, with a tolerable safety profile, according to the results of a phase II trial.

The trial randomized 103 intermediate-risk prostate cancer patients undergoing primary EBRT to 24 weeks of treatment with either once-daily oral relugolix (320 mg loading dose on day 1, and then 120 mg daily thereafter; experimental arm, n=65) or subcutaneous depot degarelix (240 mg loading dose on day 1, and then 80 mg every 4 weeks; control arm, n=38).

Effective castration (testosterone level <1.73 nmol/l) occurred in 95 percent of patients on relugolix and in 89 percent of those on degarelix, while profound castration (testosterone level <0.7 nmol/l) was recorded in 82 percent and 68 percent of patients, respectively. Median time to castration in the experimental arm was 4 days.

During treatment, prostate-specific antigen (PSA) levels and prostate volume decreased on either treatment. Testosterone recovery occurred 3 months following treatment discontinuation in 52 percent of patients in the relugolix arm and in 16 percent in the degarelix arm. Quality of life also improved after cessation of treatment.

The most common adverse event was hot flush, documented in 57 percent of patients on relugolix and in 61 percent of those on degarelix. One potential study limitation was the lack of blinding.

Relugolix is being evaluated in an ongoing global phase III trial, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
Pearl Toh, 5 days ago
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.
Elvira Manzano, 20 Jun 2018
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.